A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

This is a Phase II, single-arm, multicenter trial for patients with metastatic non-small cell lung cancer who have brain metastases and no known actionable mutations. Eligible patients will receive a combination of Datopotamab-deruxtecan, Carboplatin, and Pembrolizumab every three weeks for four cycles, followed by maintenance therapy with Datopotamab-deruxtecan and Pembrolizumab until disease progression or intolerable toxicity. Patients with intracranial progression but no systemic progression may receive stereotactic radiosurgery and continue treatment based on the investigator's decision.

Start Date30 Jun 2025

Sponsor / Collaborator

Merck Sharp & Dohme LLC

[+1]

NCT06676917

/ Not yet recruitingPhase 2

A Multicenter, Open-label, Non-comparative, Single-arm, Phase II Trial of Datopotamab Deruxtecan for Non-small Cell Lung Cancer Patients with Active Brain Metastases (The TUXEDO-5 Study)

This trial will study a type of advanced lung cancer that is defined as non-squamous non-small cell lung cancer (NSCLC) with active brain metastases (BMs). This type of cancer originates in peripheral lung tissue, which is composed of cancer cells that look different from normal lung cells when viewed under a microscope and is characterized by the presence of BMs, which indicates the spreading of such cancer cells into the brain. NSCLC tumors often have specific genetic alterations or mutations that drive their growth and are known as actionable genomic alterations (AGA). This trial will include patients with NSCLC tumors characterized by the presence or absence of such AGA. Patients will be treated with datopotamab deruxtecan (Dato-DXd), a Tumor-associated calcium signal transducer 2 (TROP2)-directed antibody drug conjugate (ADC) that works by targeting TROP2 protein that is differentially expressed in cancer cells. The main purpose of the study is to analyze the efficacy (to find out how effective a treatment is) of Dato-DXd in patients who have NSCLC with active BMs. Dato-DXd efficacy will be determined by assessing the proportion of patients who experience a significant reduction in tumor size or whose cancer disappears completely, as determined at any timepoint during the study period by the investigators conducting the trial.

Start Date01 Apr 2025

Sponsor / Collaborator

Medica Scientia Innovation Research SL

[+1]

CTR20250759

/ RecruitingPhase 3

一项评估Datopotamab Deruxtecan（Dato-DXd）和Rilvegostomig（AZD2936）联合治疗或Rilvegostomig单药治疗相比帕博利珠单抗单药治疗用于PD-L1高表达（TC≥50%）且无驱动基因改变的局部晚期或转移性非鳞状细胞NSCLC受试者一线治疗的随机、开放性、全球III期研究（TROPION-Lung10）

[Translation] A randomized, open-label, global, phase III study evaluating the combination of datopotamab deruxtecan (Dato-DXd) and rilvegostomig (AZD2936) or rilvegostomig alone versus pembrolizumab alone as a first-line treatment for patients with locally advanced or metastatic non-squamous NSCLC who have high PD-L1 expression (TC ≥ 50%) and no driver genetic alterations (TROPION-Lung10)

本研究的目的是评估Dato-DXd与rilvegostomig联合使用或rilvegostomig单药治疗相对于pembrolizumab单药治疗作为一线疗法在局部晚期或转移性高PD-L1表达（TC ≥ 50%）且无可靶向基因改变的非鳞状非小细胞肺癌参与者中的疗效和安全性。

[Translation]

The purpose of this study is to evaluate the efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy versus pembrolizumab monotherapy as first-line therapy in participants with locally advanced or metastatic nonsquamous NSCLC with high PD-L1 expression (TC ≥ 50%) and no targetable genetic alterations.

Start Date26 Mar 2025

Sponsor / Collaborator

AstraZeneca Global R&D (China) Co., Ltd.

[+1]

100 Clinical Results associated with Datopotamab Deruxtecan

100 Translational Medicine associated with Datopotamab Deruxtecan

100 Patents (Medical) associated with Datopotamab Deruxtecan

Literatures (Medical) associated with Datopotamab Deruxtecan

31 Dec 2025·mAbs

Antibodies to watch in 2025

Review

Author: Kapoor, Vaishali ; Crescioli, Silvia ; Kaplon, Hélène ; Reichert, Janice M. ; Visweswaraiah, Jyothsna ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

01 Dec 2025·Current Neurology and Neuroscience Reports

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Review

Author: Gowda, Maya ; Camacho, Alejandra M ; Ranjan, Tulika ; Ahluwalia, Manmeet S ; Podder, Vivek

PURPOSE OF REVIEW:

Advancements in precision medicine have shifted the treatment paradigm of brain metastases (BM) from non-small cell lung cancer (NSCLC), breast cancer, and melanoma, especially through targeted therapies focused on specific molecular drivers. These novel agents have improved outcomes by overcoming challenges posed by the blood-brain barrier (BBB) and resistance mechanisms, enabling more effective treatment of BM.

RECENT FINDINGS:

In NSCLC, therapies such as osimertinib have improved efficacy in treating EGFR-mutant BM, with emerging combinations such as amivantamab and lazertinib offering promising alternatives for patients resistant to frontline therapies. In HER2-positive breast cancer, significant advancements with tucatinib and trastuzumab deruxtecan (T-DXd) have transformed the treatment landscape, achieving improved survival and intracranial control in patients with BM. Similarly, in triple-negative breast cancer (TNBC), novel therapies such as sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) offer new hope for managing BM. For melanoma, the combination of immune checkpoint inhibitors such as nivolumab and ipilimumab has proven effective in enhancing survival for patients with BM, both in BRAF-mutant and wild-type cases. Developing targeted therapies penetrating the BBB has revolutionized BM treatment by targeting key drivers like EGFR, ALK, HER2, and BRAF. Despite improved survival, challenges persist, particularly for patients with resistant genetic alterations. Future research should optimise combination therapies, overcome resistance, and refine treatment sequencing. Continued emphasis on personalized, biomarker-driven approaches offers the potential to further improve outcomes, even for complex cases.

01 Apr 2025·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future

Review

Author: Santoro, Armando ; Saltalamacchia, Giuseppe ; Benvenuti, Chiara ; Torrisi, Rosalba ; Gerosa, Riccardo ; Miggiano, Chiara

Despite the impressive improvements achieved by endocrine therapy and CDK4/6 inhibitors (CDK4/6i) and the forthcoming availability of alternative endocrine manipulations and targeted therapies, hormone-receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC) is almost inevitably destined to become endocrine- refractory. At this time chemotherapy has been recently challenged and partly replaced by new targeted options as antibody-drug conjugated (ADCs). Trastuzumab-deruxtecan has been proven meaningfully superior to chemotherapy either in 1st and later lines after progression to CDK4/6i in HER2-low ABC and results with other ADCs as Sacituzumab Govitecan and Datopotamab-deruxtecan are promising, but the definition of cross-resistance between these drugs sharing either antibody or payload is crucial before implementing them in a useful sequence. While PARP inhibitors are the standard 2nd line in patients with gBRCA mutation, it is not still known whether patients with mutations of PALB2 or of other homologous recombinant defect (HRD)-related genes will benefit of the same treatment. On the other hand, the results obtained with immune checkpoint inhibitors (ICIs) in HR+ /HER2-ABC contrarily to the early setting are disappointing up to now, but investigations of ICIs in combination with other targeted drugs which may increase immune response and the search for better markers of activity are under way. Moreover the anticipation in upfront treatment of ADCs or PARPi in patients with features of putative endocrine resistance and/or of less sensitiviy to CDK4/6i and the choice of therapy in patients recurring during or soon after adjuvant CDK4/6i and olaparib represent further challenges for the future.

371

News (Medical) associated with Datopotamab Deruxtecan

29 Apr 2025

·www.globenewswire.com

Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods. This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology. Basel, 29 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the VENTANA® TROP2 (EPR20043) RxDx Device. This is the first Breakthrough Device Designation to be granted for a computational pathology companion diagnostic (CDx) device. “This FDA Breakthrough Device Designation is another example of our commitment to deliver innovation that enables more precise diagnosis in oncology,” said Matt Sause, CEO of Roche Diagnostics. “This solution, which leverages our industry-leading expertise in companion diagnostics development, uses artificial intelligence for a greater depth of sample analysis, helping to deliver truly personalised treatment.” The VENTANA TROP2 (EPR20043) RxDx Device is a computational pathology device, consisting of the TROP2 algorithm, navify® Digital Pathology Image Management System, Roche Digital Pathology scanners (DP 200, DP 600) and the VENTANA TROP2 (EPR20043) RxDx Assay used with OptiView DAB Detection Kit for staining on a BenchMark ULTRA IHC/ISH staining instrument. The VENTANA TROP2 (EPR20043) RxDx Device analyses whole slide images of non-small cell lung cancer (NSCLC) tissue stained with TROP2 to compute a quantitative TROP2 score. The algorithm incorporates AstraZeneca’s proprietary computational pathology platform, Quantitative Continuous Scoring (QCS), which enables a level of diagnostic precision not possible with traditional manual scoring methods. “This FDA Breakthrough Device Designation underscores the potential of our computational pathology platform to enable more personalised treatment decisions for people with cancer,” said Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca. The FDA granting Breakthrough Device Designation has the potential to make a TROP2 CDx AI-driven system available sooner, which could aid in identifying patients with NSCLC most likely to benefit from treatment with Daiichi Sankyo and AstraZeneca’s DATROWAY® (datopotamab deruxtecan-dlnk). DATROWAY is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo. About the VENTANA TROP2 (EPR20043) RxDx Device The VENTANA TROP2 (EPR20043) RxDx Device is indicated as an aid in identifying patients with previously treated advanced or metastatic non-squamous NSCLC without actionable genomic alteration (AGA) most likely to benefit from treatment with Daiichi Sanko and AstraZeneca’s DATROWAY (datopotamab deruxtecan-dlnk). A qualified pathologist is responsible for reviewing staining and image quality, as well as ensuring adequate tumor detection sensitivity and precision, in conjunction with histological examination, relevant clinical information, and proper controls. Following the pathologist assessment, the nDP TROP2 algorithm independently detects tumor cells and generates associated measures of TROP2 IHC staining intensity in both membrane and cytoplasm to compute the Normalised Membrane Ratio (NMR) score. The algorithm then classifies the TROP2 status as positive or negative based upon the pre-defined NMR cutoff. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Nina Mählitz Phone: +41 79 327 54 74 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachment 29042025_MR_BDD for VENTANA TROP2 RxDx Device _en

Breakthrough TherapyDiagnostic Reagents

28 Apr 2025

·www.fiercepharma.com

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch'

Daiichi Sankyo reported sales of 1.4 billion Japanese yen ($10 million) for promising antibody-drug conjugate Datroway, which was approved in Japan in December and in the U.S. in January. As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu. But so far, so good for the TROP2-directed treatment, which was endorsed in Japan in December and in the U.S. in January. Through the end of March—which concluded Daiichi’s fiscal year—Datroway generated (PDF) sales of 1.4 billion Japanese yen ($10 million).It was an indication of a “smooth market launch,” Daiichi CEO Hiroyuki Okuzawa said on a conference call late last week.Datroway has been approved for unresectable or metastatic, hormone receptor positive, HER2-negative breast cancer in patients who have tried prior endocrine-based therapy and chemotherapy.A much larger market opportunity awaits for Datroway, however, as a potential treatment for non-small cell lung cancer (NSCLC). Its entrance into the indication could come in the second half of this year as the companies are awaiting a July 12 FDA decision date for Datroway to treat patients with EGFR-mutated NSCLC who have received prior systemic therapies.The submission came after the companies pulled their original FDA filing for Datroway in second-line nonsquamous NSCLC after the phase 3 Tropion-Lung01 study showed mixed results. The pair has refiled in pretreated EGFR-mutated NSCLC using a pooled subgroup analysis from Tropion-Lung01 and the phase 2 Tropion-Lung05 trial. For now, Daiichi is projecting sales of Datroway in the new fiscal year to reach 4.7 billion Japanese yen ($33 million). As the company works to hit that goal, a recent approval in Europe should help.In 2020, AZ made a big bet on Datroway, paying Daiichi $1 billion upfront and committing up to $5 billion tied to potential regulatory and sales milestones. AZ has projected peak sales of Datroway at $5 billion.Datroway is competing with Gilead Sciences' TROP2-targeted ADC Trodelvy, which has been on the market since 2020, has been approved in three indications and generated sales of $1.3 billion last year. Earlier this month, Gilead reported a key trial win as a combination of Trodelvy and Merck’s Keytruda bested Keytruda alone in patients with previously untreated metastatic triple-negative breast cancer. The bright expectations for Datroway have come following the success of Enhertu, which logged sales of $3.7 billion in Daiichi's 2024 fiscal year. The company is projecting sales of the treatment to reach 662 billion Japanese yen in this fiscal year ($4.6 billion).As for the company overall, Daiichi’s revenue came in at 1.886 trillion Japanese yen ($13.2 billion) for the year, which was an 18% increase from FY 2023.The Tokyo-based company expects to see a slowdown in growth in this fiscal year, estimating its sales will reach 2 trillion Japanese yen ($14 billion), or roughly a 6% increase. The projection does not include any potential tariff implications, Daiichi said.

Clinical ResultDrug ApprovalPhase 3ADC

21 Apr 2025

·endpts.com

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Gilead’s antibody-drug conjugate Trodelvy combined with Merck’s Keytruda reduced the risk of disease progression or death in a key study of an aggressive form of breast cancer. Gilead announced Monday that the Phase 3 study, known as ASCENT-04, compared the combination to Keytruda plus chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer. The patients’ tumors also had to express PD-L1, a protein that’s part of the immune checkpoint system that Keytruda blocks. It’s a much-needed success for Trodelvy, which had a series of failures last year. Gilead said that the study met its primary endpoint of progression-free survival, but it did not include any crucial numbers in the press release. The Foster City, CA-based company said detailed results from the study will be presented at a future medical meeting. It also said it plans to discuss the results with regulatory bodies, though a company spokesperson declined to share specific timelines for submitting marketing applications. In its most recent earnings call in February, Gilead chief medical officer Dietmar Berger said the company hopes to bring Trodelvy to market in first-line metastatic triple-negative breast cancer as early as 2026. Another key endpoint — overall survival — was not mature at the time of analysis, though Gilead noted that there was an “early trend” of survival improvement in patients who received Trodelvy combined with Keytruda. In the Phase 3 study, the combination’s safety was “consistent with the known safety profile of each agent,” Gilead said. Trodelvy, a TROP2-directed ADC, is currently approved as a third option in metastatic triple-negative breast cancer and fourth option for HR+/HER2- breast cancer. Gilead has been seeking to expand Trodelvy’s use in breast cancer as well as in other forms of cancer, though those efforts have been bumpy. Gilead pulled Trodelvy’s accelerated approval label in bladder cancer last year after the drug failed to improve survival in a clinical trial. The antibody-drug conjugate also failed a pivotal lung cancer study in 2024. Gilead is studying Trodelvy alongside Keytruda as a post-surgery treatment for triple-negative breast cancer and in a form of lung cancer. It’s also testing Trodelvy as a standalone treatment compared to chemotherapy in metastatic triple-negative breast cancer patients who aren’t candidates for an immune checkpoint drug. That Phase 3 trial is expected to read out in the coming months. In January, Daiichi Sankyo and AstraZeneca won approval for their TROP2-directed antibody-drug conjugate Datroway in a form of breast cancer despite mixed clinical trial outcomes.

Phase 3Clinical ResultADCImmunotherapyDrug Approval

100 Deals associated with Datopotamab Deruxtecan

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16410

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	Canada	AstraZeneca Canada, Inc.	01 Mar 2025
Hormone receptor positive HER2 negative breast cancer	Japan	Daiichi Sankyo Co., Ltd.	27 Dec 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	United States	Daiichi Sankyo Co., Ltd.	12 Nov 2024
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	United States	AstraZeneca PLC	12 Nov 2024
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma	NDA/BLA	United States	Daiichi Sankyo, Inc.	19 Feb 2024
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma	NDA/BLA	United States	AstraZeneca PLC	19 Feb 2024
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	NDA/BLA	United States	AstraZeneca PLC	19 Feb 2024
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	NDA/BLA	United States	Daiichi Sankyo, Inc.	19 Feb 2024
Adenocarcinoma of Lung	Phase 3	United States	AstraZeneca PLC	15 Oct 2024
Adenocarcinoma of Lung	Phase 3	Japan	AstraZeneca PLC	15 Oct 2024
Adenocarcinoma of Lung	Phase 3	Belgium	AstraZeneca PLC	15 Oct 2024
Adenocarcinoma of Lung	Phase 3	Brazil	AstraZeneca PLC	15 Oct 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04484142 (TROPION-Lung05, Pubmed \| J Clin Oncol)	Phase 2	metastatic non-small cell lung cancer EGFR mutations \| ALK rearrangements	137	Datopotamab deruxtecan 6 mg/kg	vkvhvygtwm(zrkckvlsrh) = gjkpsjfdcy eavapihysh (cgsgppzwyu, 27.8 - 44.4) View more	Positive	01 Apr 2025
NCT03944772 (ORCHARD, ESMO_ELCC2025) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer Second line EGFRm	69	Osimertinib (80 mg QD) + Datopotamab Deruxtecan (4 mg/kg Q3W)	pcvxgrnmmi(wskkphqbxy) = zwaufbfmuj tpilbyexlx (bwfixtigmd, 31 - 55) View more	Positive	26 Mar 2025
				Osimertinib (80 mg QD) + Datopotamab Deruxtecan (6 mg/kg Q3W)	pcvxgrnmmi(wskkphqbxy) = xsijqvolio tpilbyexlx (bwfixtigmd, 25 - 49) View more
ESMO_ELCC2025	Not Applicable	Non-Small Cell Lung Cancer TROP2	914	Datopotamab deruxtecan 6 mg/kg	kxbefkhiod(xmozqmpdhv) = 7% kfrpwhbftq (goncucuuna ) View more	Positive	26 Mar 2025
NCT04656652 (TROPION-LUNG01, ESMO_ELCC2025)	Phase 3	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	468	Datopotamab deruxtecan (Dato-DXd) 6 mg/kg Q3W	zamyubdfio(pubdknjcus): HR = 1.64 (95% CI, 1.09 - 2.46) View more	Positive	26 Mar 2025
				Docetaxel 75 mg/m2 Q3W
NCT05460273 (TROPION-PanTumor02, ESMO_ELCC2025)	Phase 1/2	Non-Small Cell Lung Cancer TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR)	40	datopotamab deruxtecan (TROP2 QCS-NMR+ tumors)	hwjwjdeucp(aimszbwkaq) = cgzekvuysj eiznkgbdpi (gqikyjvkei, 0.32 - 0.77) View more	Positive	26 Mar 2025
				datopotamab deruxtecan (TROP2 QCS-NMR- tumors)	hwjwjdeucp(aimszbwkaq) = sidkdcqaxy eiznkgbdpi (gqikyjvkei, 0.10 - 0.53) View more
NCT04612751 (TROPION-Lung04, ESMO_TAT2025) Manual	Phase 1	Non-Small Cell Lung Cancer First line	52	Dato-DXd + Durvalumab	isggzjwmgn(esmqyamjrj) = kqscmlypsc xaquvefdxb (cufbpsokbw ) View more	Positive	03 Mar 2025
				Dato-DXd + Durvalumab + Carboplatin	isggzjwmgn(esmqyamjrj) = clzpmozqps xaquvefdxb (cufbpsokbw ) View more
NCT03401385 (TROPION-PanTumor01, ASCO_GU2025) Manual	Phase 1	Transitional Cell Carcinoma	40	Dato-DXd 6mg/kg	pfyvggkjbc(byvwrhbawa) = vkjzglmhws wsbuumgjph (otzqvnarja, 12.7 41.2) View more	Positive	13 Feb 2025
NCT05104866 (TROPION-Breast01, FDA_CDER) Manual	Phase 3	Hormone receptor positive HER2 negative breast cancer Second line \| Third line	732	DATROWAY 6 mg/kgDATROWAY 6 mg/kg	bimuzcchpc(oopqnpluya) = iwajjiwnpu bsjgolbfha (newdjwhryz, 5.7 - 7.4) View more	Positive	17 Jan 2025
				Chemotherapy	bimuzcchpc(oopqnpluya) = retkpkbgjn bsjgolbfha (newdjwhryz, 4.2 - 5.5) View more
NCT04484142 (TROPION-Lung05, Pubmed) Manual	Phase 2	metastatic non-small cell lung cancer Last line ALK Rearrangement \| EGFR Mutation	137	Datopotamab deruxtecan 6 mg/kg	ewockwyzfw(rhnhcpvbgv) = veinileajs vzvotldujh (sbdgulspnr, 27.8 - 44.4) View more	Positive	06 Jan 2025
				Datopotamab deruxtecan 6 mg/kg (EGFR mutations)	ewockwyzfw(rhnhcpvbgv) = nnnzhoezze vzvotldujh (sbdgulspnr, 32.4 - 55.3)
NCT05104866 (TROPION-Breast01, ESMO_ASIA2024) Manual	Phase 3	Hormone receptor positive HER2 negative breast cancer Hormone Receptor Positive \| HER2 Negative	83	Datopotamab deruxtecan (Dato-DXd) (China cohort)	ktpqzvzysp(cwwvblzlxb) = ihsrullvfj hohimfaylo (ykiuosnkcx ) View more	Positive	07 Dec 2024
				Chemotherapy (capecitabine/eribulin/gemcitabine/vinorelbine) (China cohort)	ktpqzvzysp(cwwvblzlxb) = dkghcsvwca hohimfaylo (ykiuosnkcx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis